Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase - PubMed

Affiliations

• PMID: 19848404
• DOI: 10.1021/jm9012642

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase

Pawel Nowak et al. J Med Chem. 2009.

Abstract

The mammalian target of rapamycin (mTOR) is a central regulator of cell growth, metabolism, and angiogenesis and an emerging target in cancer research. High throughput screening (HTS) of our compound collection led to the identification of 3-(4-morpholin-4-yl-1-piperidin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenol (5a), a modestly potent and nonselective inhibitor of mTOR and phosphoinositide 3-kinase (PI3K). Optimization of compound 5a, employing an mTOR homology model based on an X-ray crystal structure of closely related PI3Kgamma led to the discovery of 6-(1H-indol-5-yl)-4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidine (5u), a potent and selective mTOR inhibitor (mTOR IC(50) = 9 nM; PI3Kalpha IC(50) = 1962 nM). Compound 5u selectively inhibited cellular biomarker of mTORC1 (P-S6K, P-4EBP1) and mTORC2 (P-AKT S473) over the biomarker of PI3K/PDK1 (P-AKT T308) and did not inhibit PI3K-related kinases (PIKKs) in cellular assays. These pyrazolopyrimidines represent an exciting new series of mTOR-selective inhibitors with potential for development for cancer therapy.

Similar articles

• Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

  Verheijen JC, Richard DJ, Curran K, Kaplan J, Lefever M, Nowak P, Malwitz DJ, Brooijmans N, Toral-Barza L, Zhang WG, Lucas J, Hollander I, Ayral-Kaloustian S, Mansour TS, Yu K, Zask A. Verheijen JC, et al. J Med Chem. 2009 Dec 24;52(24):8010-24. doi: 10.1021/jm9013828. J Med Chem. 2009. PMID: 19894727

• Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.

  Menear KA, Gomez S, Malagu K, Bailey C, Blackburn K, Cockcroft XL, Ewen S, Fundo A, Le Gall A, Hermann G, Sebastian L, Sunose M, Presnot T, Torode E, Hickson I, Martin NM, Smith GC, Pike KG. Menear KA, et al. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5898-901. doi: 10.1016/j.bmcl.2009.08.069. Epub 2009 Aug 21. Bioorg Med Chem Lett. 2009. PMID: 19733066

• A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.

  Lee W, Ortwine DF, Bergeron P, Lau K, Lin L, Malek S, Nonomiya J, Pei Z, Robarge KD, Schmidt S, Sideris S, Lyssikatos JP. Lee W, et al. Bioorg Med Chem Lett. 2013 Sep 15;23(18):5097-104. doi: 10.1016/j.bmcl.2013.07.027. Epub 2013 Jul 23. Bioorg Med Chem Lett. 2013. PMID: 23932790

• Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.

  Richard DJ, Verheijen JC, Zask A. Richard DJ, et al. Curr Opin Drug Discov Devel. 2010 Jul;13(4):428-40. Curr Opin Drug Discov Devel. 2010. PMID: 20597028 Review.

• PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.

  Brachmann S, Fritsch C, Maira SM, García-Echeverría C. Brachmann S, et al. Curr Opin Cell Biol. 2009 Apr;21(2):194-8. doi: 10.1016/j.ceb.2008.12.011. Epub 2009 Feb 7. Curr Opin Cell Biol. 2009. PMID: 19201591 Review.

Cited by

• Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.

  Liao YJ, Hsu SM, Chien CY, Wang YH, Hsu MH, Suk FM. Liao YJ, et al. Molecules. 2020 Jun 20;25(12):2856. doi: 10.3390/molecules25122856. Molecules. 2020. PMID: 32575795 Free PMC article.

• Pd-Catalyzed Cross-Couplings: On the Importance of the Catalyst Quantity Descriptors, mol % and ppm.

  Horbaczewskyj CS, Fairlamb IJS. Horbaczewskyj CS, et al. Org Process Res Dev. 2022 Aug 19;26(8):2240-2269. doi: 10.1021/acs.oprd.2c00051. Epub 2022 Jul 11. Org Process Res Dev. 2022. PMID: 36032362 Free PMC article. Review.

• Software and resources for computational medicinal chemistry.

  Liao C, Sitzmann M, Pugliese A, Nicklaus MC. Liao C, et al. Future Med Chem. 2011 Jun;3(8):1057-85. doi: 10.4155/fmc.11.63. Future Med Chem. 2011. PMID: 21707404 Free PMC article. Review.

• From laptop to benchtop to bedside: structure-based drug design on protein targets.

  Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L, Zhang S. Chen L, et al. Curr Pharm Des. 2012;18(9):1217-39. doi: 10.2174/138161212799436386. Curr Pharm Des. 2012. PMID: 22316152 Free PMC article. Review.

• Chemical and Structural Strategies to Selectively Target mTOR Kinase.

  Borsari C, De Pascale M, Wymann MP. Borsari C, et al. ChemMedChem. 2021 Sep 16;16(18):2744-2759. doi: 10.1002/cmdc.202100332. Epub 2021 Jul 1. ChemMedChem. 2021. PMID: 34114360 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Chemical Information

  • BindingDB

• Miscellaneous

  • NCI CPTAC Assay Portal